Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 13:20:42 UTC 2023
by
admin
on
Sat Dec 16 13:20:42 UTC 2023
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
JMN849I3XV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
P28907
Created by
admin on Sat Dec 16 13:20:43 UTC 2023 , Edited by admin on Sat Dec 16 13:20:43 UTC 2023
|
PRIMARY | |||
|
JMN849I3XV
Created by
admin on Sat Dec 16 13:20:43 UTC 2023 , Edited by admin on Sat Dec 16 13:20:43 UTC 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_67 | 1_82 |
| 1_99 | 1_180 |
| 1_160 | 1_173 |
| 1_254 | 1_275 |
| 1_287 | 1_296 |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_100 |
| N | 1_164 |
| N | 1_209 |
| N | 1_219 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR -> TARGET |
depletes human tumor cells expressing CD38 by antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
|
||
|
INHIBITOR -> TARGET |
ADCC and ADCP are considered to be primary modes of action for MOR202 targeting CD38 high expressing cells.
EC50
|
||
|
|
LIGAND->TARGET |
|
||
|
|
LIGAND->TARGET | |||
|
RADIOLIGAND->TARGET |
|
||
|
|
LIGAND->TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
SUBSTRATE -> METABOLIC ENZYME |
|
||
|
LIGAND->TARGET |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|